Schrodinger (SDGR) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $22.60, -11.30% vs the prior close of $25.48.
- Volume 2.72M shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SDGR slides 11.3% to $22.60, a 1-month low. Closed at $22.60, -11.30% vs the prior close of $25.48. Day range $22.57–$26.00, opened at $25.69.
SDGR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — SDGR slides 11.3% to $22.60, a 1-month low
- Closed at $22.60, -11.30% vs the prior close of $25.48. Day range $22.57–$26.00, opened at $25.69.
- Volume was 2.72M shares, 1.3x its 50-day average of 2.11M.
- Price is -4.0% vs its 50-day average ($23.53) and +37.8% vs its 200-day average ($16.40).
- 52-week range $10.94–$33.78; today's close sits at 51% of that range, 33.1% below the 52-week high.
Oct 15, 2026 — SDGR rises 1.7% to $25.48
- Closed at $25.48, +1.72% vs the prior close of $25.05. Day range $24.01–$26.14, opened at $24.50.
- Volume was 2.37M shares, 1.1x its 50-day average of 2.09M.
- Price is +8.7% vs its 50-day average ($23.44) and +55.6% vs its 200-day average ($16.37).
- 52-week range $10.94–$33.78; today's close sits at 64% of that range, 24.6% below the 52-week high.
Oct 14, 2026 — SDGR slides 3.2% to $25.05, 3 down days in a row
- Closed at $25.05, -3.24% vs the prior close of $25.89. Day range $24.96–$25.80, opened at $25.36.
- Volume was 1.29M shares, 0.6x its 50-day average of 2.09M.
- Price is +7.7% vs its 50-day average ($23.25) and +53.3% vs its 200-day average ($16.34).
- 52-week range $10.94–$33.78; today's close sits at 62% of that range, 25.8% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — SDGR ends flat (-0.1%) to $25.89
- Closed at $25.89, -0.08% vs the prior close of $25.91. Day range $25.50–$26.23, opened at $25.71.
- Volume was 1.30M shares, 0.6x its 50-day average of 2.08M.
- Price is +12.2% vs its 50-day average ($23.07) and +58.8% vs its 200-day average ($16.30).
- 52-week range $10.94–$33.78; today's close sits at 65% of that range, 23.4% below the 52-week high.
Oct 12, 2026 — SDGR slides 5.0% to $25.91
- Closed at $25.91, -5.02% vs the prior close of $27.28. Day range $25.41–$27.51, opened at $27.10.
- Volume was 2.15M shares, 1.0x its 50-day average of 2.06M.
- Price is +13.4% vs its 50-day average ($22.85) and +59.3% vs its 200-day average ($16.26).
- 52-week range $10.94–$33.78; today's close sits at 66% of that range, 23.3% below the 52-week high.
Oct 9, 2026 — SDGR jumps 3.4% to $27.28
- Closed at $27.28, +3.37% vs the prior close of $26.39. Day range $26.37–$28.16, opened at $26.61.
- Volume was 2.08M shares, 1.0x its 50-day average of 2.04M.
- Price is +20.5% vs its 50-day average ($22.64) and +68.1% vs its 200-day average ($16.23).
- 52-week range $10.94–$33.78; today's close sits at 72% of that range, 19.2% below the 52-week high.
Oct 8, 2026 — SDGR slides 3.3% to $26.39, 3 down days in a row
- Closed at $26.39, -3.30% vs the prior close of $27.29. Day range $25.69–$27.05, opened at $26.79.
- Volume was 3.08M shares, 1.5x its 50-day average of 1.99M.
- Price is +17.8% vs its 50-day average ($22.40) and +63.0% vs its 200-day average ($16.19).
- 52-week range $10.94–$33.78; today's close sits at 68% of that range, 21.9% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — SDGR slides 5.6% to $27.29 on 2.4x normal volume
- Closed at $27.29, -5.57% vs the prior close of $28.90. Day range $26.87–$28.43, opened at $27.81.
- Volume was 4.56M shares, 2.4x its 50-day average of 1.91M — unusually heavy trading.
- Price is +23.1% vs its 50-day average ($22.17) and +69.0% vs its 200-day average ($16.15).
- 52-week range $10.94–$33.78; today's close sits at 72% of that range, 19.2% below the 52-week high.
Oct 6, 2026 — SDGR slides 11.3% to $28.90 on 2.9x normal volume
- Closed at $28.90, -11.35% vs the prior close of $32.60. Day range $28.56–$33.78, opened at $32.99.
- Volume was 5.26M shares, 2.9x its 50-day average of 1.82M — unusually heavy trading.
- Price is +31.8% vs its 50-day average ($21.93) and +79.6% vs its 200-day average ($16.09).
- 52-week range $10.94–$33.78; today's close sits at 79% of that range, 14.4% below the 52-week high.
Oct 5, 2026 — SDGR jumps 7.6% to $32.60, a 52-week high on 2.6x normal volume
- Closed at $32.60, +7.56% vs the prior close of $30.31. Day range $29.56–$33.09, opened at $30.33.
- Volume was 4.61M shares, 2.6x its 50-day average of 1.74M — unusually heavy trading.
- Price is +50.5% vs its 50-day average ($21.66) and +103.3% vs its 200-day average ($16.04).
- 52-week range $10.94–$33.09; today's close sits at 98% of that range, 1.5% below the 52-week high.
Oct 2, 2026 — SDGR dips 0.5% to $30.31
- Closed at $30.31, -0.49% vs the prior close of $30.46. Day range $29.28–$31.14, opened at $30.74.
- Volume was 3.05M shares, 1.8x its 50-day average of 1.70M.
- Price is +42.2% vs its 50-day average ($21.31) and +89.9% vs its 200-day average ($15.96).
- 52-week range $10.94–$32.45; today's close sits at 90% of that range, 6.6% below the 52-week high.
SDGR latest news & SEC filings
Every SEC filing by or about SDGR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Akinsanya Karen converted options/RSUs into 31,599 shares at $4.34 (≈$137.14K) on Sep 17, 2026; now holds 101,555
- Akinsanya Karen sold 10,000 shares at $28.00 (≈$280.00K) on Sep 17, 2026; now holds 91,555
- Akinsanya Karen sold 21,599 shares at $30.00 (≈$647.97K) on Sep 17, 2026; now holds 69,956
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 5, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $58.89M (prior year $54.76M) (+7.5% vs Jun 30, 2025)
- Net income: $5.97M (prior year -$43.17M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $0.08 (prior year -$0.59) (swung to profit vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Jain Rachit sold 875 shares at $15.60 (≈$13.65K) on Jul 16, 2026
- Jain Rachit sold 875 shares at $15.60 (≈$13.65K) on Jul 16, 2026
- Jain Rachit sold 875 shares at $15.60 (≈$13.65K) on Jul 16, 2026
- Jain Rachit sold 875 shares at $15.60 (≈$13.65K) on Jul 16, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 16, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jun 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade SDGR
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 25, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.78% (largest 11.3%). That is a volatile stock.
- Liquidity: about 2.87M shares (≈$64.89M) trade per day on average.
- 52-week position: $22.60 vs a range of $10.94–$33.78 (51% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Karen Akinsanya sold 10,000 shares on Sep 17, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K Jun 29, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
SDGR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 25.69 | 26.00 | 22.57 | 22.60 | 2.72M |
| Oct 15, 2026 | 24.50 | 26.14 | 24.01 | 25.48 | 2.37M |
| Oct 14, 2026 | 25.36 | 25.80 | 24.96 | 25.05 | 1.29M |
| Oct 13, 2026 | 25.71 | 26.23 | 25.50 | 25.89 | 1.30M |
| Oct 12, 2026 | 27.10 | 27.51 | 25.41 | 25.91 | 2.15M |
| Oct 9, 2026 | 26.61 | 28.16 | 26.37 | 27.28 | 2.08M |
| Oct 8, 2026 | 26.79 | 27.05 | 25.69 | 26.39 | 3.08M |
| Oct 7, 2026 | 27.81 | 28.43 | 26.87 | 27.29 | 4.56M |
| Oct 6, 2026 | 32.99 | 33.78 | 28.56 | 28.90 | 5.26M |
| Oct 5, 2026 | 30.33 | 33.09 | 29.56 | 32.60 | 4.61M |
| Oct 2, 2026 | 30.74 | 31.14 | 29.28 | 30.31 | 3.05M |
| Oct 1, 2026 | 30.77 | 31.93 | 30.01 | 30.46 | 5.14M |
| Sep 30, 2026 | 30.55 | 32.45 | 30.18 | 31.05 | 3.89M |
| Sep 29, 2026 | 29.30 | 30.60 | 29.04 | 30.33 | 1.86M |
| Sep 28, 2026 | 28.47 | 30.21 | 28.20 | 29.50 | 2.13M |
| Sep 25, 2026 | 29.60 | 29.74 | 27.69 | 28.85 | 1.37M |
| Sep 24, 2026 | 28.97 | 30.24 | 28.40 | 29.45 | 2.03M |
| Sep 23, 2026 | 30.05 | 31.14 | 28.32 | 29.23 | 3.07M |
| Sep 22, 2026 | 30.13 | 31.59 | 29.69 | 30.70 | 2.58M |
| Sep 21, 2026 | 29.43 | 31.03 | 29.00 | 30.24 | 2.89M |
About Schrodinger
Schrodinger (SDGR) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW YORK, NY. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1490978.
SDGR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jeffrey Chodakewitz | Director | Jun 23, 2026 |
| Ramy Farid | President & CEO | Apr 17, 2026 |
| Richard Friesner | Director | Jun 29, 2026 |
| Gary L Ginsberg | Director | Jun 23, 2026 |
| Rosana Kapeller-Libermann | Director | Jun 23, 2026 |
| Michael Lynton | Director | Jun 23, 2026 |
| Arun Oberoi | Director | Jun 23, 2026 |
| Gary Sender | Director | Jun 23, 2026 |
| Nancy Thornberry | Director | Jun 23, 2026 |
| Kralingen Bridget A Van | Director | Jun 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Robert Lorne Abel | See Remarks | Mar 6, 2026 |
| Therese Marie Abrams | VP, Corporate Controller | Mar 19, 2026 |
| Karen Akinsanya | See Remarks | Sep 21, 2026 |
| Mannix Vartan Aklian | See Remarks | Mar 3, 2026 |
| Margaret Dugan | Chief Medical Officer | Oct 17, 2025 |
| Ramy Farid | President & CEO | Apr 17, 2026 |
| Jenny Herman | CAO | Mar 6, 2026 |
| Rachit Jain | EVP & CFO | Jul 17, 2026 |
| Kenneth Patrick Lorton | EVP, CTO & COO, Software | Mar 6, 2026 |
| Yvonne Tran | EVP, CLO & CPO | Mar 6, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 17, 2026 | Karen Akinsanya | Sale | 10,000 | $28.00 |
| Sep 17, 2026 | Karen Akinsanya | Sale | 21,599 | $30.00 |
| Sep 17, 2026 | Karen Akinsanya | Sale | 10,000 | $28.00 |
| Sep 17, 2026 | Karen Akinsanya | Sale | 21,599 | $30.00 |
| Sep 17, 2026 | Karen Akinsanya | Sale | 10,000 | $28.00 |
| Sep 17, 2026 | Karen Akinsanya | Sale | 21,599 | $30.00 |
| Sep 17, 2026 | Karen Akinsanya | Sale | 10,000 | $28.00 |
| Sep 17, 2026 | Karen Akinsanya | Sale | 21,599 | $30.00 |
| Jul 16, 2026 | Rachit Jain | Sale | 875 | $15.60 |
| Jul 16, 2026 | Rachit Jain | Sale | 875 | $15.60 |
| Jul 16, 2026 | Rachit Jain | Sale | 875 | $15.60 |
| Jul 16, 2026 | Rachit Jain | Sale | 875 | $15.60 |
| Apr 17, 2026 | Ramy Farid | Sale | 43,000 | $12.21 |
| Apr 17, 2026 | Ramy Farid | Sale | 43,000 | $12.21 |
| Apr 17, 2026 | Ramy Farid | Sale | 43,000 | $12.21 |
SDGR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $255.87M | $-103.27M | -1.41 | $13.90M |
| Dec 31, 2024 | $207.54M | $-187.12M | -2.57 | $-157.37M |
| Dec 31, 2023 | $216.67M | $40.72M | 0.54 | $-136.73M |
| Dec 31, 2022 | $180.96M | $-149.19M | -2.10 | $-119.68M |
| Dec 31, 2021 | $137.93M | $-100.39M | -1.42 | $-70.67M |
Latest balance sheet: total assets $640.39M, total liabilities $311.44M, cash $287.85M (as of Jun 30, 2026).
SDGR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $16.40 |
| May 5, 2026 | 8-K Item 2.02 (results) | $12.87 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $11.80 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $19.77 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $19.34 |
| May 7, 2025 | 8-K Item 2.02 (results) | $23.72 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $21.70 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $22.25 |
| Jul 31, 2024 | 8-K Item 2.02 (results) | — |
| May 1, 2024 | 8-K Item 2.02 (results) | — |
| Feb 28, 2024 | 8-K Item 2.02 (results) | — |
| Nov 1, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on SDGR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.